लोड हो रहा है...
EGFR inhibition in non-small cell lung cancer: current evidence and future directions
EGFR inhibition has emerged to be an important strategy in the treatment of non-small cell lung cancer (NSCLC). Small molecule tyrosine kinase inhibitors (TKIs) and mono-clonal antibodies (mAbs) to the EGFR have been tested in multiple large randomized phase III studies alone or combined with chemot...
में बचाया:
मुख्य लेखकों: | , , |
---|---|
स्वरूप: | Artigo |
भाषा: | Inglês |
प्रकाशित: |
BioMed Central
2013
|
विषय: | |
ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3776244/ https://ncbi.nlm.nih.gov/pubmed/24252457 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2050-7771-1-2 |
टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|